| Literature DB >> 30352558 |
Jae Shin Choi1, Seon Ha Baek2, Ho Jun Chin3,4, Ki Young Na3,4, Dong-Wan Chae3,4, Yon Su Kim3, Sejoong Kim5,6, Seung Seok Han7.
Abstract
BACKGROUNDS: Knowledge on cross-talk between the heart and kidney has been established by basic and clinical research. Nevertheless, the effects of systolic and diastolic heart dysfunctions on the development of acute kidney injury (AKI) and end-stage renal disease (ESRD) remain unresolved in hospitalized patients.Entities:
Keywords: Acute kidney injury; Diastolic dysfunction; Echocardiography; End-stage renal disease; Systolic dysfunction
Mesh:
Year: 2018 PMID: 30352558 PMCID: PMC6199698 DOI: 10.1186/s12882-018-1103-2
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Baseline characteristics of the study patients
| Variable | Total ( | Non-AKI ( | AKI ( |
|
|---|---|---|---|---|
| Age (year) | 66.2 ± 13.4 | 66.1 ± 0.4 | 66.9 ± 1.1 | 0.104 |
| Men (%) | 52.4 | 52.8 | 50.0 | 0.453 |
| Body mass index (kg/m2) | 24.2 ± 3.7 | 24.3 ± 0.1 | 23.2 ± 0.3 | < 0.001 |
| Systolic BP (mmHg) | 129.5 ± 20.0 | 130.3 ± 0.6 | 125.5 ± 1.6 | 0.001 |
| Diastolic BP (mmHg) | 73.6 ± 12.7 | 74.3 ± 0.4 | 70.3 ± 1.0 | < 0.001 |
| Comorbidities (%) | ||||
| Hypertension | 42.0 | 40.5 | 50.0 | 0.010 |
| Diabetes mellitus | 32.4 | 28.6 | 52.4 | < 0.001 |
| Ischemic heart disease | 21.1 | 23.3 | 9.0 | < 0.001 |
| Cerebrovascular disease | 6.1 | 6.2 | 5.7 | 0.797 |
| Heart failure | 2.1 | 1.5 | 5.2 | 0.001 |
| Cancer | 31.3 | 29.8 | 39.5 | 0.005 |
| Medications (%) | ||||
| Alpha blocker | 0.9 | 0.6 | 2.4 | 0.014 |
| ACE inhibitor | 5.3 | 4.8 | 7.6 | 0.098 |
| ARB | 17.9 | 17.0 | 22.4 | 0.062 |
| Beta-blocker | 18.6 | 19.2 | 15.7 | 0.239 |
| Calcium channel blocker | 16.5 | 14.8 | 25.7 | < 0.001 |
| Diuretics | 14.0 | 9.2 | 4.8 | < 0.001 |
| Laboratory findings | ||||
| Hemoglobin (g/dL) | 12.2 ± 2.1 | 12.4 ± 0.06 | 10.9 ± 0.1 | < 0.001 |
| Albumin (g/dL) | 3.9 ± 0.6 | 3.9 ± 0.02 | 3.5 ± 0.04 | < 0.001 |
| Glucose (mg/dL) | 134.3 ± 56.8 | 130.4 ± 1.6 | 149.6 ± 4.8 | < 0.001 |
| Cholesterol (mg/dL) | 157.3 ± 41.6 | 160.3 ± 1.2 | 141.6 ± 3.3 | < 0.001 |
| eGFR (ml/min/1.73 m2) | 82.5 ± 24.1 | 83.0 ± 20.6 | 79.9 ± 37.7 | 0.376 |
| Echocardiographic findings | ||||
| LVMI (g/m2) | 95.8 ± 26.5 | 95.3 ± 0.8 | 98.5 ± 2.1 | 0.220 |
| EF (%) | 61.6 ± 8.8 | 61.9 ± 0.3 | 60.3 ± 0.7 | 0.027 |
| E/A | 0.9 ± 0.4 | 0.9 ± 0.01 | 0.9 ± 0.03 | 0.228 |
| E/e’ | 10.3 ± 4.9 | 10.1 ± 0.1 | 11.6 ± 0.4 | 0.001 |
| RWMA (%) | 8.8 | 8.6 | 10.0 | 0.510 |
AKI acute kidney injury, BP blood pressure, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, eGFR estimated glomerular filtration rate, LVMI left ventricular mass index, EF ejection fraction, E early diastolic transmitral inflow velocity, A late diastolic transmitral flow velocity, e’ early diastolic mitral annular velocity, RWMA regional wall motion abnormality
Odds ratios of acute kidney injury according to the echocardiographic parameters
| Univariate | Multivariatea | |||||
|---|---|---|---|---|---|---|
| Parameters | Range | OR (95% CI) |
| OR (95% CI) |
| |
| Ejection fraction | 4th quartile ( | > 67.1 | 1 (Reference) | 1 (Reference) | ||
| 3rd quartile ( | 63.1–67.1 | 1.07 (0.693–1.644) | 0.768 | 1.08 (0.663–1.748) | 0.765 | |
| 2nd quartile ( | 58.5–63.0 | 1.08 (0.705–1.658) | 0.720 | 1.27 (0.788–2.039) | 0.328 | |
| 1st quartile ( | < 58.5 | 1.60 (1.069–2.409) | 0.023 | 1.74 (1.035–2.917) | 0.037 | |
| E/e’ | 1st quartile ( | < 7.2 | 1 (Reference) | 1 (Reference) | ||
| 2nd quartile ( | 7.2–9.2 | 1.12 (0.723–1.747) | 0.604 | 1.15 (0.699–1.888) | 0.583 | |
| 3rd quartile ( | 9.3–11.9 | 1.04 (0.668–1.632) | 0.850 | 1.06 (0.635–1.777) | 0.817 | |
| 4th quartile ( | > 11.9 | 1.90 (1.257–2.877) | 0.002 | 1.63 (0.954–2.787) | 0.074 | |
| Combined parameterb | 1st group ( | – | 1 (Reference) | 1 (Reference) | ||
| 2nd group ( | – | 1.20 (0.836–1.719) | 0.325 | 1.33 (0.895–1.977) | 0.158 | |
| 3rd group ( | – | 1.68 (1.026–2.743) | 0.039 | 1.49 (0.852–2.612) | 0.162 | |
| 4th group ( | – | 2.27 (1.490–3.446) | < 0.001 | 1.95 (1.192–3.201) | 0.008 | |
aAdjusted for age, sex, body mass index, comorbidities, medications, laboratory findings, and other echocardiography findings
bCombined parameter: 1st group, 1st to 3rd quartiles of E/e’ plus 3rd to 4th quartiles of ejection fraction; 2nd group, 1st to 3rd quartiles of E/e’ plus 1st to 2nd quartiles of ejection fraction; 3rd group, 4th quartile of E/e’ plus 3rd to 4th quartiles of ejection fraction; 4th group, 4th quartile of E/e’ plus 1st to 2nd quartiles of ejection fraction
OR odds ratio, CI confidence interval, E early diastolic transmitral inflow velocity, A late diastolic transmitral flow velocity, e’ early diastolic mitral annular velocity
Fig. 1Nonlinear relations between predicted probability of AKI and echocardiographic parameters, (a) E/e’ and (b) LVEF. Fitted line and 95% confidence intervals are indicated as solid and shaded area, respectively
Fig. 2Curves obtained using the Kaplan-Meier method of rates of ESRD according to groups. a E/e’ and (b) LVEF
Hazard ratios of end-stage renal disease according to the echocardiographic parameters
| Univariate | Multivariatea | ||||
|---|---|---|---|---|---|
| Parameters | HR (95% CI) |
| HR (95% CI) |
| |
| Ejection fraction | 4th quartile ( | 1 (Reference) | 1 (Reference) | ||
| 3rd quartile ( | 0.22 (0.026–1.881) | 0.167 | 0.26 (0.067–1.027) | 0.055 | |
| 2nd quartile ( | 1.51 (0.478–4.749) | 0.484 | 0.79 (0.226–2.746) | 0.708 | |
| 1st quartile ( | 1.33 (0.405–4.348) | 0.641 | 0.12 (0.013–1.093) | 0.060 | |
| E/e’ | 1st quartile ( | 1 (Reference) | 1 (Reference) | ||
| 2nd quartile ( | 0.64 (0.107–3.828) | 0.624 | 2.31 (0.171–31.098) | 0.528 | |
| 3rd quartile ( | 0.64 (0.106–3.806) | 0.620 | 0.94 (0.076–11.629) | 0.961 | |
| 4th quartile ( | 4.13 (1.165–14.635) | 0.028 | 5.20 (0.548–49.273) | 0.151 | |
| Combined parameterb | 1st group ( | 1 (Reference) | 1 (Reference) | ||
| 2nd group ( | 1.55 (0.347–6.930) | 0.566 | 1.44 (0.234–8.819) | 0.695 | |
| 3rd group ( | 4.09 (0.825–20.258) | 0.085 | 4.02 (0.517–31.282) | 0.183 | |
| 4th group ( | 8.81 (2.386–32.554) | 0.001 | 3.57 (0.596–21.340) | 0.164 | |
aAdjusted for age, sex, body mass index, comorbidities, medications, laboratory findings, and other echocardiography findings
bCombined parameter: 1st group, 1st to 3rd quartiles of E/e’ plus 3rd to 4th quartiles of ejection fraction; 2nd group, 1st to 3rd quartiles of E/e’ plus 1st to 2nd quartiles of ejection fraction; 3rd group, 4th quartile of E/e’ plus 3rd to 4th quartiles of ejection fraction; 4th group, 4th quartile of E/e’ plus 1st to 2nd quartiles of ejection fraction
HR hazard ratio, CI confidence interval, E early diastolic transmitral inflow velocity, A late diastolic transmitral flow velocity, e’ early diastolic mitral annular velocity
Fig. 3Risk of ESRD according to the presence of AKI and heart dysfunction. Combined parameter (CP) is defined using the median of LVEF and quartiles of E/e’, as follows: 1st group, 1st to 3rd quartiles of E/e’ plus 3rd to 4th quartiles of ejection fraction; 2nd group, 1st to 3rd quartiles of E/e’ plus 1st to 2nd quartiles of ejection fraction; 3rd group, 4th quartile of E/e’ plus 3rd to 4th quartiles of ejection fraction; 4th group, 4th quartile of E/e’ plus 1st to 2nd quartiles of ejection fraction
Comparison between the areas under the receiver operating characteristic curves of echocardiographic models
| Reference | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|
| AUC (95% CI) | AUC (95% CI) | AUC (95% CI) | AUC (95% CI) | ||||
| AKI | 0.695 (0.657–0.733) | 0.705 (0.668–0.742) | 0.065 | 0.703 (0.665–0.740) | 0.161 | 0.709 (0.672–0.745) | 0.027 |
| 3-year ESRD | 0.788 (0.669–0.907) | 0.795 (0.677–0.913) | 0.536 | 0.819 (0.686–0.951) | 0.204 | 0.819 (0.688–0.951) | 0.182 |
Reference model: age, sex, body mass index, diabetes, ischemic heart disease, and cerebrovascular disease
Model 1: reference model plus ejection fraction
Model 2: reference model plus E/e’
Model 3: reference model plus combined parameter
*Difference is calculated in comparison to the reference model
AUC area under the curve, CI confidence interval, AKI acute kidney injury, ESRD end-stage renal disease
Continuous NRI and IDI indices when the echocardiographic parameters are added in the AKI- or ESRD-predicting model
| Outcome | Parameter | cNRI (95% CI) | IDI (95% CI) | ||
|---|---|---|---|---|---|
| AKI | Model 1 | 0.109 (− 0.038–0.256) | 0.145 | 0.008 (0.000–0.002) | 0.053 |
| Model 2 | 0.211 (0.065–0.356) | 0.005 | 0.001 (0.000–0.002) | 0.013 | |
| Model 3 | 0.148 (0.000–0.295) | 0.049 | 0.002 (0.001–0.004) | 0.001 | |
| 3-year ESRD | Model 1 | 0.283 (−0.154–0.720) | 0.204 | 0.000 (−0.000–0.001) | 0.423 |
| Model 2 | 0.477 (0.077–0.876) | 0.019 | 0.002 (0.000–0.003) | 0.008 | |
| Model 3 | 0.685 (0.314–1.055) | < 0.001 | 0.003 (0.001–0.005) | < 0.001 |
Reference model: age, sex, body mass index, diabetes, ischemic heart disease, and cerebrovascular disease
Model 1: reference model plus ejection fraction
Model 2: reference model plus E/e’
Model 3: reference model plus combined parameter
*Difference is calculated in comparison to the reference model. cNRI continuous net reclassification improvement, IDI integrated discrimination improvement, AKI acute kidney injury, ESRD end-stage renal disease